Share Price and Basic Stock Data
Last Updated: October 16, 2025, 6:21 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
ANG Lifesciences India Ltd operates within the pharmaceuticals sector, showcasing a market capitalization of ₹43.0 Cr and a current share price of ₹32.9. The company reported sales figures that peaked at ₹349 Cr in March 2022 but saw a significant decline to ₹207 Cr in March 2023, followed by a further drop to ₹131 Cr for March 2024. Quarterly sales trends indicate volatility, with ₹71.56 Cr in June 2022 decreasing to ₹31.88 Cr by March 2023, and later recovering to ₹50.61 Cr in June 2023. However, the latest figure for September 2023 stood at ₹29.58 Cr, suggesting ongoing challenges in revenue stability. The operating profit margin (OPM) fluctuated, recording a low of -36.39% in March 2023 and a modest recovery to 7.58% as of the latest quarter. This revenue inconsistency reflects broader operational challenges that ANG Lifesciences faces within the competitive pharmaceutical industry.
Profitability and Efficiency Metrics
The profitability metrics of ANG Lifesciences reveal a concerning trend, with a net profit of -₹10 Cr for the fiscal year ending March 2025. The company has struggled with profitability, as evidenced by a negative profit before tax of ₹-13 Cr, reflecting operational inefficiencies. The return on equity (ROE) stood at 13.8%, which is relatively low compared to industry standards, while the return on capital employed (ROCE) was significantly lower at 3.54%. The interest coverage ratio (ICR) was alarmingly low at -0.02x, indicating that the company is unable to meet its interest obligations through its earnings. Additionally, the cash conversion cycle (CCC) extended to 158.34 days, pointing to inefficiencies in managing working capital. These profitability and efficiency challenges highlight the need for ANG Lifesciences to implement strategic changes to enhance operational performance and financial health.
Balance Sheet Strength and Financial Ratios
ANG Lifesciences’ balance sheet reflects a precarious financial position, with total borrowings amounting to ₹70.58 Cr against reserves of ₹53.75 Cr. This results in a debt-to-equity ratio of 1.26, indicating a reliance on debt financing that could pose risks in a rising interest rate environment. The company’s current ratio stood at 1.15, suggesting a marginally adequate liquidity position, while the quick ratio of 0.77 raises concerns about its ability to meet short-term liabilities without relying on inventory. The book value per share has declined from ₹80.81 in March 2022 to ₹48.99 in March 2025, reflecting a decrease in shareholders’ equity. Furthermore, the price-to-book value ratio of 0.46x suggests that the stock is undervalued relative to its book value, though this may also indicate market skepticism about the company’s future profitability. These financial ratios underscore the challenges ANG Lifesciences faces in maintaining a robust balance sheet amidst declining earnings.
Shareholding Pattern and Investor Confidence
The shareholding structure of ANG Lifesciences indicates a strong promoter presence, with promoters holding 70.60% of the shares, which reflects a solid commitment to the company’s future. The public holds 29.40% of the shares, showing a stable interest among retail investors. However, the lack of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) could indicate a lack of confidence from larger investment entities, which may be wary due to the company’s recent financial performance. The number of shareholders has seen a decline, decreasing from 7,163 in March 2023 to 6,400 by June 2025, suggesting potential disenchantment among retail investors. This decreasing shareholder base may pose risks to the company’s market perception and support, emphasizing the need for ANG Lifesciences to restore investor confidence through improved financial performance and transparency.
Outlook, Risks, and Final Insight
If ANG Lifesciences can stabilize its revenue and improve operational efficiencies, there is potential for a turnaround in profitability. However, significant risks remain, including high debt levels, operational inefficiencies, and declining sales trends, all of which need to be addressed promptly. The company must focus on enhancing its cash flow management and reducing its cash conversion cycle to improve liquidity. Additionally, strengthening its product portfolio and exploring new market opportunities could help regain investor confidence and attract institutional interest. A strategic review of cost structures and operational processes may also be essential to return to a positive profit trajectory. Overall, while challenges are evident, targeted actions could pave the way for potential recovery and growth in the future.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of ANG Lifesciences India Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 149 Cr. | 119 | 247/84.3 | 34.0 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,671 Cr. | 430 | 435/192 | 105 | 22.8 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 39.8 Cr. | 53.6 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 30.8 Cr. | 21.0 | 29.1/17.0 | 32.1 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,723.32 Cr | 1,181.55 | 49.94 | 193.63 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 71.56 | 58.39 | 45.17 | 31.88 | 50.61 | 29.58 | 17.10 | 34.08 | 16.18 | 32.16 | 23.91 | 17.67 | 24.53 |
| Expenses | 60.28 | 49.15 | 43.03 | 43.48 | 44.94 | 28.26 | 18.82 | 30.23 | 18.11 | 29.70 | 25.89 | 18.03 | 22.67 |
| Operating Profit | 11.28 | 9.24 | 2.14 | -11.60 | 5.67 | 1.32 | -1.72 | 3.85 | -1.93 | 2.46 | -1.98 | -0.36 | 1.86 |
| OPM % | 15.76% | 15.82% | 4.74% | -36.39% | 11.20% | 4.46% | -10.06% | 11.30% | -11.93% | 7.65% | -8.28% | -2.04% | 7.58% |
| Other Income | 0.12 | 0.20 | 0.32 | 9.20 | 0.34 | 0.33 | -0.09 | -1.49 | 1.36 | 0.36 | -0.03 | 0.75 | 0.17 |
| Interest | 3.17 | 3.20 | 2.84 | 1.11 | 1.94 | 1.96 | 1.99 | 3.44 | 1.67 | 1.87 | 1.71 | 2.05 | 1.61 |
| Depreciation | 1.88 | 1.90 | 1.92 | 2.82 | 1.94 | 1.97 | 2.02 | 1.83 | 1.51 | 1.62 | 1.84 | 1.30 | 1.45 |
| Profit before tax | 6.35 | 4.34 | -2.30 | -6.33 | 2.13 | -2.28 | -5.82 | -2.91 | -3.75 | -0.67 | -5.56 | -2.96 | -1.03 |
| Tax % | 47.24% | 39.63% | -30.43% | -20.54% | 25.35% | -10.09% | -20.96% | 23.71% | -26.13% | 61.19% | -17.99% | -34.46% | -23.30% |
| Net Profit | 3.34 | 2.62 | -1.60 | -5.03 | 1.60 | -2.05 | -4.59 | -3.60 | -2.77 | -1.07 | -4.57 | -1.94 | -0.79 |
| EPS in Rs | 2.57 | 2.02 | -1.23 | -3.85 | 1.23 | -1.57 | -3.52 | -2.76 | -2.12 | -0.82 | -3.50 | -1.49 | -0.60 |
Last Updated: August 19, 2025, 11:45 pm
Below is a detailed analysis of the quarterly data for ANG Lifesciences India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 24.53 Cr.. The value appears strong and on an upward trend. It has increased from 17.67 Cr. (Mar 2025) to 24.53 Cr., marking an increase of 6.86 Cr..
- For Expenses, as of Jun 2025, the value is 22.67 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 18.03 Cr. (Mar 2025) to 22.67 Cr., marking an increase of 4.64 Cr..
- For Operating Profit, as of Jun 2025, the value is 1.86 Cr.. The value appears strong and on an upward trend. It has increased from -0.36 Cr. (Mar 2025) to 1.86 Cr., marking an increase of 2.22 Cr..
- For OPM %, as of Jun 2025, the value is 7.58%. The value appears strong and on an upward trend. It has increased from -2.04% (Mar 2025) to 7.58%, marking an increase of 9.62%.
- For Other Income, as of Jun 2025, the value is 0.17 Cr.. The value appears to be declining and may need further review. It has decreased from 0.75 Cr. (Mar 2025) to 0.17 Cr., marking a decrease of 0.58 Cr..
- For Interest, as of Jun 2025, the value is 1.61 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.05 Cr. (Mar 2025) to 1.61 Cr., marking a decrease of 0.44 Cr..
- For Depreciation, as of Jun 2025, the value is 1.45 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.30 Cr. (Mar 2025) to 1.45 Cr., marking an increase of 0.15 Cr..
- For Profit before tax, as of Jun 2025, the value is -1.03 Cr.. The value appears strong and on an upward trend. It has increased from -2.96 Cr. (Mar 2025) to -1.03 Cr., marking an increase of 1.93 Cr..
- For Tax %, as of Jun 2025, the value is -23.30%. The value appears to be increasing, which may not be favorable. It has increased from -34.46% (Mar 2025) to -23.30%, marking an increase of 11.16%.
- For Net Profit, as of Jun 2025, the value is -0.79 Cr.. The value appears strong and on an upward trend. It has increased from -1.94 Cr. (Mar 2025) to -0.79 Cr., marking an increase of 1.15 Cr..
- For EPS in Rs, as of Jun 2025, the value is -0.60. The value appears strong and on an upward trend. It has increased from -1.49 (Mar 2025) to -0.60, marking an increase of 0.89.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:57 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 34.50 | 36.84 | 54.92 | 66.93 | 75.13 | 121.27 | 126.08 | 154.24 | 348.52 | 206.82 | 131.30 | 89.73 | 98.27 |
| Expenses | 29.61 | 33.72 | 50.19 | 60.43 | 67.83 | 109.63 | 113.65 | 138.91 | 282.98 | 195.15 | 121.75 | 90.75 | 96.29 |
| Operating Profit | 4.89 | 3.12 | 4.73 | 6.50 | 7.30 | 11.64 | 12.43 | 15.33 | 65.54 | 11.67 | 9.55 | -1.02 | 1.98 |
| OPM % | 14.17% | 8.47% | 8.61% | 9.71% | 9.72% | 9.60% | 9.86% | 9.94% | 18.81% | 5.64% | 7.27% | -1.14% | 2.01% |
| Other Income | 0.12 | 0.09 | 0.21 | 0.25 | 0.69 | 0.23 | 0.42 | 0.75 | 0.95 | 9.84 | -0.89 | 1.99 | 1.25 |
| Interest | 1.51 | 1.66 | 1.66 | 1.77 | 1.85 | 2.64 | 3.22 | 3.98 | 8.31 | 10.92 | 9.77 | 7.64 | 7.24 |
| Depreciation | 3.05 | 0.95 | 1.06 | 1.17 | 1.19 | 1.12 | 1.23 | 2.24 | 5.12 | 8.52 | 7.75 | 6.27 | 6.21 |
| Profit before tax | 0.45 | 0.60 | 2.22 | 3.81 | 4.95 | 8.11 | 8.40 | 9.86 | 53.06 | 2.07 | -8.86 | -12.94 | -10.22 |
| Tax % | 55.56% | 31.67% | 25.23% | 25.98% | 24.65% | 30.33% | 27.50% | 26.47% | 25.18% | 131.88% | -2.48% | -20.02% | |
| Net Profit | 0.19 | 0.40 | 1.65 | 2.82 | 3.72 | 5.65 | 6.10 | 7.25 | 39.71 | -0.66 | -8.65 | -10.34 | -8.37 |
| EPS in Rs | 0.21 | 0.43 | 1.79 | 3.07 | 2.86 | 4.35 | 4.69 | 5.58 | 30.55 | -0.51 | -6.62 | -7.92 | -6.41 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2.61% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 110.53% | 312.50% | 70.91% | 31.91% | 51.88% | 7.96% | 18.85% | 447.72% | -101.66% | -1210.61% | -19.54% |
| Change in YoY Net Profit Growth (%) | 0.00% | 201.97% | -241.59% | -38.99% | 19.97% | -43.92% | 10.89% | 428.87% | -549.39% | -1108.94% | 1191.07% |
ANG Lifesciences India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -7% |
| 3 Years: | -36% |
| TTM: | 1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 28% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | -45% |
| 1 Year: | -48% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 9% |
| 3 Years: | -8% |
| Last Year: | -14% |
Last Updated: September 5, 2025, 2:16 pm
Balance Sheet
Last Updated: October 10, 2025, 3:27 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.68 | 3.68 | 3.68 | 3.68 | 5.18 | 5.18 | 5.18 | 5.18 | 10.37 | 13.06 | 13.06 | 13.06 |
| Reserves | -0.97 | -0.57 | 1.09 | 3.81 | 17.99 | 23.58 | 29.37 | 36.17 | 73.11 | 72.48 | 64.01 | 53.75 |
| Borrowings | 11.03 | 10.15 | 11.77 | 14.01 | 17.42 | 21.90 | 20.83 | 42.40 | 60.99 | 55.56 | 59.36 | 70.58 |
| Other Liabilities | 11.44 | 12.59 | 18.95 | 25.34 | 27.57 | 30.24 | 38.69 | 58.49 | 124.21 | 111.40 | 81.00 | 71.28 |
| Total Liabilities | 25.18 | 25.85 | 35.49 | 46.84 | 68.16 | 80.90 | 94.07 | 142.24 | 268.68 | 252.50 | 217.43 | 208.67 |
| Fixed Assets | 9.04 | 8.78 | 9.02 | 8.90 | 9.47 | 20.60 | 20.94 | 21.89 | 82.32 | 78.68 | 53.35 | 52.63 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.07 | 11.57 | 0.16 | 0.23 | 0.40 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 3.52 | 3.52 | 3.52 | 3.52 |
| Other Assets | 16.12 | 17.05 | 26.45 | 37.85 | 47.10 | 60.12 | 72.88 | 119.93 | 182.84 | 170.30 | 160.56 | 152.52 |
| Total Assets | 25.18 | 25.85 | 35.49 | 46.84 | 68.16 | 80.90 | 94.07 | 142.24 | 268.68 | 252.50 | 217.43 | 208.67 |
Below is a detailed analysis of the balance sheet data for ANG Lifesciences India Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 13.06 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 13.06 Cr..
- For Reserves, as of Mar 2025, the value is 53.75 Cr.. The value appears to be declining and may need further review. It has decreased from 64.01 Cr. (Mar 2024) to 53.75 Cr., marking a decrease of 10.26 Cr..
- For Borrowings, as of Mar 2025, the value is 70.58 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 59.36 Cr. (Mar 2024) to 70.58 Cr., marking an increase of 11.22 Cr..
- For Other Liabilities, as of Mar 2025, the value is 71.28 Cr.. The value appears to be improving (decreasing). It has decreased from 81.00 Cr. (Mar 2024) to 71.28 Cr., marking a decrease of 9.72 Cr..
- For Total Liabilities, as of Mar 2025, the value is 208.67 Cr.. The value appears to be improving (decreasing). It has decreased from 217.43 Cr. (Mar 2024) to 208.67 Cr., marking a decrease of 8.76 Cr..
- For Fixed Assets, as of Mar 2025, the value is 52.63 Cr.. The value appears to be declining and may need further review. It has decreased from 53.35 Cr. (Mar 2024) to 52.63 Cr., marking a decrease of 0.72 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 3.52 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 3.52 Cr..
- For Other Assets, as of Mar 2025, the value is 152.52 Cr.. The value appears to be declining and may need further review. It has decreased from 160.56 Cr. (Mar 2024) to 152.52 Cr., marking a decrease of 8.04 Cr..
- For Total Assets, as of Mar 2025, the value is 208.67 Cr.. The value appears to be declining and may need further review. It has decreased from 217.43 Cr. (Mar 2024) to 208.67 Cr., marking a decrease of 8.76 Cr..
However, the Borrowings (70.58 Cr.) are higher than the Reserves (53.75 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -6.14 | -7.03 | -7.04 | -7.51 | -10.12 | -10.26 | -8.40 | -27.07 | 4.55 | -43.89 | -49.81 | -71.60 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 79.67 | 62.22 | 108.86 | 139.39 | 156.19 | 125.66 | 133.34 | 139.10 | 103.67 | 137.85 | 192.56 | 264.24 |
| Inventory Days | 83.99 | 84.14 | 46.81 | 44.62 | 53.41 | 27.18 | 41.03 | 67.62 | 46.29 | 92.90 | 143.34 | 227.95 |
| Days Payable | 129.49 | 129.88 | 133.28 | 163.44 | 153.96 | 90.63 | 105.80 | 158.84 | 105.16 | 153.93 | 243.56 | 333.86 |
| Cash Conversion Cycle | 34.17 | 16.48 | 22.39 | 20.58 | 55.64 | 62.21 | 68.56 | 47.88 | 44.80 | 76.83 | 92.34 | 158.34 |
| Working Capital Days | 28.25 | 18.73 | 10.23 | 14.40 | 48.29 | 39.70 | 52.60 | 47.14 | 22.05 | 27.88 | 74.97 | 71.80 |
| ROCE % | 13.65% | 16.74% | 26.04% | 29.34% | 21.90% | 23.56% | 21.92% | 19.90% | 53.78% | 8.51% | 1.78% | -3.54% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -9.42 | -7.65 | 0.36 | 39.39 |
| Diluted EPS (Rs.) | -9.42 | -7.65 | 0.36 | 39.09 |
| Cash EPS (Rs.) | -4.33 | -1.36 | 6.96 | 44.56 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 48.99 | 58.41 | 66.02 | 80.81 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 48.99 | 58.41 | 66.02 | 80.81 |
| Revenue From Operations / Share (Rs.) | 71.10 | 111.89 | 168.39 | 341.77 |
| PBDIT / Share (Rs.) | -0.19 | 7.92 | 18.27 | 65.87 |
| PBIT / Share (Rs.) | -5.37 | 1.51 | 11.11 | 60.20 |
| PBT / Share (Rs.) | -12.03 | -8.20 | 2.01 | 51.61 |
| Net Profit / Share (Rs.) | -9.51 | -7.77 | -0.20 | 38.89 |
| NP After MI And SOA / Share (Rs.) | -9.51 | -7.77 | -0.20 | 38.89 |
| PBDIT Margin (%) | -0.27 | 7.07 | 10.84 | 19.27 |
| PBIT Margin (%) | -7.55 | 1.34 | 6.59 | 17.61 |
| PBT Margin (%) | -16.91 | -7.33 | 1.19 | 15.10 |
| Net Profit Margin (%) | -13.36 | -6.94 | -0.11 | 11.37 |
| NP After MI And SOA Margin (%) | -13.36 | -6.94 | -0.11 | 11.37 |
| Return on Networth / Equity (%) | -19.40 | -13.29 | -0.30 | 48.12 |
| Return on Capital Employeed (%) | -8.14 | 2.01 | 12.35 | 50.02 |
| Return On Assets (%) | -5.40 | -4.18 | -0.09 | 13.85 |
| Long Term Debt / Equity (X) | 0.29 | 0.18 | 0.23 | 0.25 |
| Total Debt / Equity (X) | 1.26 | 0.90 | 0.81 | 0.91 |
| Asset Turnover Ratio (%) | 0.39 | 0.55 | 0.77 | 0.00 |
| Current Ratio (X) | 1.15 | 1.24 | 1.15 | 1.16 |
| Quick Ratio (X) | 0.77 | 0.90 | 0.85 | 0.93 |
| Inventory Turnover Ratio (X) | 1.25 | 2.14 | 3.65 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 2.57 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 2.24 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 97.43 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 97.76 |
| Interest Coverage Ratio (X) | -0.02 | 0.94 | 2.01 | 7.67 |
| Interest Coverage Ratio (Post Tax) (X) | -0.42 | 0.23 | 0.97 | 5.53 |
| Enterprise Value (Cr.) | 106.47 | 122.38 | 163.11 | 313.54 |
| EV / Net Operating Revenue (X) | 1.15 | 0.83 | 0.74 | 0.88 |
| EV / EBITDA (X) | -416.21 | 11.83 | 6.84 | 4.59 |
| MarketCap / Net Operating Revenue (X) | 0.31 | 0.40 | 0.45 | 0.68 |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 97.42 |
| Price / BV (X) | 0.46 | 0.77 | 1.15 | 2.90 |
| Price / Net Operating Revenue (X) | 0.31 | 0.40 | 0.45 | 0.68 |
| EarningsYield | -0.41 | -0.17 | 0.00 | 0.16 |
After reviewing the key financial ratios for ANG Lifesciences India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -9.42. This value is below the healthy minimum of 5. It has decreased from -7.65 (Mar 24) to -9.42, marking a decrease of 1.77.
- For Diluted EPS (Rs.), as of Mar 25, the value is -9.42. This value is below the healthy minimum of 5. It has decreased from -7.65 (Mar 24) to -9.42, marking a decrease of 1.77.
- For Cash EPS (Rs.), as of Mar 25, the value is -4.33. This value is below the healthy minimum of 3. It has decreased from -1.36 (Mar 24) to -4.33, marking a decrease of 2.97.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 48.99. It has decreased from 58.41 (Mar 24) to 48.99, marking a decrease of 9.42.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 48.99. It has decreased from 58.41 (Mar 24) to 48.99, marking a decrease of 9.42.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 71.10. It has decreased from 111.89 (Mar 24) to 71.10, marking a decrease of 40.79.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.19. This value is below the healthy minimum of 2. It has decreased from 7.92 (Mar 24) to -0.19, marking a decrease of 8.11.
- For PBIT / Share (Rs.), as of Mar 25, the value is -5.37. This value is below the healthy minimum of 0. It has decreased from 1.51 (Mar 24) to -5.37, marking a decrease of 6.88.
- For PBT / Share (Rs.), as of Mar 25, the value is -12.03. This value is below the healthy minimum of 0. It has decreased from -8.20 (Mar 24) to -12.03, marking a decrease of 3.83.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -9.51. This value is below the healthy minimum of 2. It has decreased from -7.77 (Mar 24) to -9.51, marking a decrease of 1.74.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -9.51. This value is below the healthy minimum of 2. It has decreased from -7.77 (Mar 24) to -9.51, marking a decrease of 1.74.
- For PBDIT Margin (%), as of Mar 25, the value is -0.27. This value is below the healthy minimum of 10. It has decreased from 7.07 (Mar 24) to -0.27, marking a decrease of 7.34.
- For PBIT Margin (%), as of Mar 25, the value is -7.55. This value is below the healthy minimum of 10. It has decreased from 1.34 (Mar 24) to -7.55, marking a decrease of 8.89.
- For PBT Margin (%), as of Mar 25, the value is -16.91. This value is below the healthy minimum of 10. It has decreased from -7.33 (Mar 24) to -16.91, marking a decrease of 9.58.
- For Net Profit Margin (%), as of Mar 25, the value is -13.36. This value is below the healthy minimum of 5. It has decreased from -6.94 (Mar 24) to -13.36, marking a decrease of 6.42.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -13.36. This value is below the healthy minimum of 8. It has decreased from -6.94 (Mar 24) to -13.36, marking a decrease of 6.42.
- For Return on Networth / Equity (%), as of Mar 25, the value is -19.40. This value is below the healthy minimum of 15. It has decreased from -13.29 (Mar 24) to -19.40, marking a decrease of 6.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is -8.14. This value is below the healthy minimum of 10. It has decreased from 2.01 (Mar 24) to -8.14, marking a decrease of 10.15.
- For Return On Assets (%), as of Mar 25, the value is -5.40. This value is below the healthy minimum of 5. It has decreased from -4.18 (Mar 24) to -5.40, marking a decrease of 1.22.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.29. This value is within the healthy range. It has increased from 0.18 (Mar 24) to 0.29, marking an increase of 0.11.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.26. This value exceeds the healthy maximum of 1. It has increased from 0.90 (Mar 24) to 1.26, marking an increase of 0.36.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.39. It has decreased from 0.55 (Mar 24) to 0.39, marking a decrease of 0.16.
- For Current Ratio (X), as of Mar 25, the value is 1.15. This value is below the healthy minimum of 1.5. It has decreased from 1.24 (Mar 24) to 1.15, marking a decrease of 0.09.
- For Quick Ratio (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 1. It has decreased from 0.90 (Mar 24) to 0.77, marking a decrease of 0.13.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.25. This value is below the healthy minimum of 4. It has decreased from 2.14 (Mar 24) to 1.25, marking a decrease of 0.89.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -0.02. This value is below the healthy minimum of 3. It has decreased from 0.94 (Mar 24) to -0.02, marking a decrease of 0.96.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -0.42. This value is below the healthy minimum of 3. It has decreased from 0.23 (Mar 24) to -0.42, marking a decrease of 0.65.
- For Enterprise Value (Cr.), as of Mar 25, the value is 106.47. It has decreased from 122.38 (Mar 24) to 106.47, marking a decrease of 15.91.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.15. This value is within the healthy range. It has increased from 0.83 (Mar 24) to 1.15, marking an increase of 0.32.
- For EV / EBITDA (X), as of Mar 25, the value is -416.21. This value is below the healthy minimum of 5. It has decreased from 11.83 (Mar 24) to -416.21, marking a decrease of 428.04.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.31. This value is below the healthy minimum of 1. It has decreased from 0.40 (Mar 24) to 0.31, marking a decrease of 0.09.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has decreased from 0.77 (Mar 24) to 0.46, marking a decrease of 0.31.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.31. This value is below the healthy minimum of 1. It has decreased from 0.40 (Mar 24) to 0.31, marking a decrease of 0.09.
- For EarningsYield, as of Mar 25, the value is -0.41. This value is below the healthy minimum of 5. It has decreased from -0.17 (Mar 24) to -0.41, marking a decrease of 0.24.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in ANG Lifesciences India Ltd:
- Net Profit Margin: -13.36%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -8.14% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -19.4% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -0.42
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.77
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 49.94)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.26
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -13.36%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Darbara Complex, Amritsar Punjab 143001 | cs@anglifesciences.com http://www.anglifesciences.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rajesh Gupta | Managing Director |
| Mrs. Saruchi Gupta | Whole Time Director |
| Mr. Rohit Mittal | Non Executive Director |
| Mr. Sukhpal Singh | Independent Director |
| Mr. Harvinder Singh | Independent Director |
| Mrs. Chetna | Independent Director |
FAQ
What is the intrinsic value of ANG Lifesciences India Ltd?
ANG Lifesciences India Ltd's intrinsic value (as of 16 October 2025) is 86.48 which is 173.67% higher the current market price of 31.60, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 41.3 Cr. market cap, FY2025-2026 high/low of 50.5/21.0, reserves of ₹53.75 Cr, and liabilities of 208.67 Cr.
What is the Market Cap of ANG Lifesciences India Ltd?
The Market Cap of ANG Lifesciences India Ltd is 41.3 Cr..
What is the current Stock Price of ANG Lifesciences India Ltd as on 16 October 2025?
The current stock price of ANG Lifesciences India Ltd as on 16 October 2025 is 31.6.
What is the High / Low of ANG Lifesciences India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of ANG Lifesciences India Ltd stocks is 50.5/21.0.
What is the Stock P/E of ANG Lifesciences India Ltd?
The Stock P/E of ANG Lifesciences India Ltd is .
What is the Book Value of ANG Lifesciences India Ltd?
The Book Value of ANG Lifesciences India Ltd is 51.2.
What is the Dividend Yield of ANG Lifesciences India Ltd?
The Dividend Yield of ANG Lifesciences India Ltd is 0.00 %.
What is the ROCE of ANG Lifesciences India Ltd?
The ROCE of ANG Lifesciences India Ltd is 3.54 %.
What is the ROE of ANG Lifesciences India Ltd?
The ROE of ANG Lifesciences India Ltd is 13.8 %.
What is the Face Value of ANG Lifesciences India Ltd?
The Face Value of ANG Lifesciences India Ltd is 10.0.